RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Directors Dealings

Home  >  Investor Relations  >  Financial Reports & SEC Filings  >  Directors Dealings

QIAGEN publishes information on directors' dealings as reported to the company and pursuant to regulations by the United States Securities and Exchange Commission (SEC) and the Netherlands Authority for the Financial Markets (A-FM) pursuant to Section 2a Wmz 1996 and Art. 19. EU Directive No. 596/2014. Our insider trading policy can be downloaded as PDF document here.

Notes to the overview of recent transactions

* Cashless Exercise

1) According to a Rule 10b5-1 long-term Sales Plan ("Langzeitverkaufsvertrag").

2) Lawrence A. Rosen, Metin Colpan, Thomas Ebeling, Toralf Haag, Ross L. Levine, Elaine R. Mardis, Eva Pisa, Elizabeth E. Tallett.

“Net share settlement” is done when a number of shares to cover expenses related to the grant release (such as taxes and transaction costs) are withheld by the Company.

Recent transactions

-->
Name and function Date and type Financial instrument Amount of shares SEC BAFin A-FM
Elaine R. Mardis,
Supervisory Director
03/14/23 Common Share 4,739 PDF PDF PDF
Lawrence A. Rosen,
Supervisory Director
02/28/23 Common Shares received through release of Restricted Stock Units ("net share settlement") 5,217

-

PDF PDF
Metin Colpan,
Supervisory Director
02/28/23 Common Shares received through release of Restricted Stock Units ("net share settlement") 4,868

-

PDF PDF
Ross L. Levine,
Supervisory Director
02/28/23 Common Shares received through release of Restricted Stock Units ("net share settlement") 4,469

-

PDF PDF
Elaine R. Mardis,
Supervisory Director
02/28/23 Common Shares received through release of Restricted Stock Units ("net share settlement") 4,739

-

PDF PDF
Elizabeth E. Tallett,
Supervisory Director
02/28/23 Common Shares received through release of Restricted Stock Units ("net share settlement") 5,277

-

PDF PDF
Thierry Bernard,
Managing Director
02/28/23 Common Shares received through release of Performance Stock Units ("net share settlement") 38,825

-

PDF PDF
Roland Sackers,
Managing Director
02/28/23 Common Shares received through release of Performance Stock Units and Restricted Stock Units ("net share settlement") 36,712

-

PDF PDF
All Supervisory Board,
Directors2)
02/28/23
Grant
Restricted Stock Units 7,917

-

PDF PDF
Thierry Bernard,
Managing Director
02/28/23
Grant
Performance Stock Units 119,695

-

PDF PDF
Roland Sackers,
Managing Director
02/28/23
Grant
Performance Stock Units 67,723

-

PDF PDF
Thierry Bernard,
Managing Director
02/21/23 Common Shares received through release of Performance Stock Units ("net share settlement") 12,987

-

PDF PDF
Roland Sackers,
Managing Director
02/21/23 Common Shares received through release of Performance Stock Units ("net share settlement") 26,653

-

PDF PDF